Skip to main content

Table 4 Clinical characteristics and prognosis in the present study compared with previous studies in some developed countries

From: A real-world study on diagnosis and prognosis of light-chain cardiac amyloidosis in Southern China

  Present study
(n = 170)
Pinney et al. [5]
(n = 36)
Sidana [6]
(n = 405)
Quarta et al. [14]
(n = 80)
Country Changsha, China London, UK Rochester, USA Boston, USA
Age at diagnosis (years) 60.81 (± 10.46) 63.0 (56.6–65.8) 65 (58–73) 62 (± 10)
Male (%) 70.59% 69% 64% 66%
Major manifestation leading diagnosis (%) HF (72.3%) HF (80.5%) NA HF (66%)
Pacemaker 8.2% 5.5% NA NA
Atrial fibrillation 17.7% 11% NA 8%
NYHA III or IV (%) 76.47% 60% NA 29%
eGFR, mL/(min × 1.73m2) 60.6 (± 31.4) 64 (48–87) 62 (46–77) 64 (± 27)
NT-proBNP, pg/mL 6139.4 (2957.7–11,754.0) 714.0 (427.5–1573.0) pmol/L 4484 (1846–10 243) 3085 (1314–11,260)
IVS, mm 14.1 (± 3.6) 15 (± 2) NA 15 (± 2)
LVPW, mm 13.6 (± 3.3) 15 (± 2) NA 14 (± 2)
LVEF, (%) 52.9 (± 10.0) 47.8 (± 12.6) NA 56 (± 14)
QTc, ms 471.6 (± 36.7) 596.6 (± 745.0) NA NA
Low voltage 57.1% 27% NA 45%
Median survival (month) 8.0 10.4 16 12
  1. Data are (N) Mean (SD) or (N) n (%), Median (Q3–Q1), where N is the total number of patients with available data. For other abbreviations, see Tables 1, 2 and 3